TBC1 domain family member 2Genealiases: PARIS-1 · PARIS1 · TBC1D2A
Q-omics provides the consensus-scored TBC1D2 profile across patient tissues and cancer cell-line models. TBC1D2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TBC1D2 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, TBC1D2 protein abundance shows 21,801 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where TBC1D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D2 survival associations across molecular data types. TBC1D2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D2 RNA expression–survival associations across cancer types. High TBC1D2 expression shows unfavorable associations in HNSC, ACC and KIRC, but favorable associations in UCEC, COAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TBC1D2 RNA expression.
This table summarizes TBC1D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D2 shows lower tumor expression in LUAD and higher tumor expression in THCA, KIRP, HNSC, KIRC and BRCA. The THCA box plot shows higher TBC1D2 RNA expression in tumor versus normal tissue (log2 FC = +2.072, t-test p < 0.001).
This table shows molecular features associated with TBC1D2 in patient tissues and cancer cell lines. In patient samples, TBC1D2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
